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Introduction and background
===========================

The number of patients with atrial fibrillation (AF) who need stroke prevention continues to rise. The prevalence of AF increases with age and is associated with a higher risk of ischemic stroke. The use of warfarin reduces the risk of ischemic stroke in patients with AF, but they need frequent monitoring and dose adjustment \[[@REF1]\]. Ischemic stroke is considered as a focal neurological deficit from non-traumatic and non-hemorrhagic causes. AF is the cause of ischemic stroke in 15% of all ages and 30% of people over 80 years of age. The risk of ischemic stroke increases significantly with anticoagulant cessation \[[@REF2]\].

The importance of a safe and effective prevention guideline with the best antiplatelets and anticoagulants combination is a major goal for medicine. Oral direct factor Xa inhibitors (xabans) are approved by the United States Food and Drug Administration (FDA) for the prevention of stroke. Warfarin is an antagonist of vitamin K. Xabans have a different effect in the clotting cascade. They act directly upon factor Xa. They have fewer drug and food interactions, and their location in the coagulation cascade promises their efficiency. There is no need to monitor their effects by checking the international normalized ratio (INR). This current review shows that xabans are at least as safe as warfarin in the elderly, patients with impaired liver and renal function, and in patients with a CHA2DS2-VASc score 2 or greater (scores that use factors like age, sex, history of stroke, hypertension and diabetes to estimate the risk of ischemic stroke in AF. A score of 2 or greater is moderate to high risk). Most physicians prefer these drugs over warfarin; however, there might be some limitations like patients' kidney and liver function and the fact that they are not yet approved for valvular AF. Physicians need to consider the risk of bleeding, and the patient's drug combination like their interaction with antiplatelet medications (like aspirin and clopidogrel).

There are some clinical benefits of xabans over warfarin. Based on current data, the best combination for the prevention of primary and secondary ischemic stroke in patients with AF would be aspirin plus clopidogrel and one xaban, such as apixaban, edoxaban, rivaroxaban, and darexaban \[[@REF3]\]. There are still some challenging questions regarding the potential benefits of xabans over warfarin: How is their efficacy in the prevention of primary and secondary strokes compared to warfarin? How are their safety (minor and major bleedings) and food and drug interaction compared to warfarin? 

The presented literature review focused on the efficacy and safety of using xabans versus warfarin in the prevention of primary and secondary ischemic strokes in patients with non-valvular AF. This information will help clinicians to improve the outcomes of patients with AF.

Review
======

Method and results

Data were collected manually on PubMed using parallel strategies derived from MeSH keywords and regular keywords. Table [1](#TAB1){ref-type="table"} represents all keywords used for this review.

###### Data regarding the number of articles obtained using regular and MeSH keywords.

  ---------------------------------------------------------------------------
  Regular and MeSH keywords
  Regular keyword: atrial fibrillation
  Total articles
  Articles selected
  Regular keyword: direct factor Xa inhibitors
  Total articles
  Articles selected
  MeSH keywords: atrial fibrillation, direct factor Xa inhibitors, warfarin
  Total articles
  Articles selected
  ---------------------------------------------------------------------------

This review has been generated after including the following inclusion/exclusion criteria. Table [2](#TAB2){ref-type="table"} represents the inclusion/exclusion criteria. 

###### The inclusion/exclusion criteria.

  ---------------------------------------------------------
  Inclusion criteria
  Studies in the English language
  Randomized controlled trials and clinical trials
  Human studies
  Studies in the last 10 years
  Studies on patients  with confirmed atrial fibrillation
  Subjects of age above 18 years
  ---------------------------------------------------------

We found 83,611 articles using the regular keyword \'atrial fibrillation\'. We noted 2,224 articles using the regular keywords: \'direct factor Xa inhibitors\' and \'atrial fibrillation\'. Finally, we obtained 326 studies using MeSH keywords: \'atrial fibrillation\', \'direct factor Xa inhibitors\', and \'warfarin\'. Ultimately, 46 articles were selected regarding the exclusion/inclusion criteria. All 46 studies that were chosen at the end had full articles available. They were all randomized controlled trials (RCTs) or clinical trials on human subjects. All articles have been in the English language since 10 years ago.

Study design 

All studies were clinical trials and RCTs. The maximum number of subjects among all reviewed articles was 21,105 and the minimum number of subjects was 45 \[[@REF4],[@REF5]\]. Among all studies, 29 studies compared different xabans with warfarin. These alternative drugs included apixaban for six studies, rivaroxaban in fifteen studies, edoxaban for seven studies, and darexaban in one study \[[@REF1]-[@REF4],[@REF6]-[@REF30]\]. Finally, six studies evaluated the effects of different types of non-vitamin K oral anticoagulants with warfarin \[[@REF5],[@REF31]-[@REF35]\]. This review shows that xabans are more efficient in the prevention of ischemic stroke in patients with non-valvular AF. There is less drug and food interaction when patients receive xabans. Also, the mortality rate, risk of major and minor bleedings, and hemorrhagic stroke are less common in patients who receive xabans compared to patients who receive warfarin.

Figure [1](#FIG1){ref-type="fig"} represents the flowchart with the selection process for this literature review. 

![The flowchart that represents the selection process of the current literature review.\
AF, atrial fibrillation; RCT, randomized controlled trial](cureus-0012-00000009400-i01){#FIG1}

Discussion

AF is correlated with a higher risk of ischemic stroke. A stroke resulting from AF is more likely to be disabling than a non-AF stroke \[[@REF28]\]. The importance of a more beneficial anticoagulant resulted in many clinical trials to compare these treatments. This review was performed to demonstrate that xabans are superior to warfarin in the prevention of ischemic stroke in patients with non-valvular AF. Also, we think that xabans have a lower rate of major and minor bleeding events and lower foods and drug interaction. We found that the majority of RCTs supported our hypothesis. We also found that xabans are at least as safe as warfarin in the elderly, patients with renal failure, patients with impaired liver function, and in patients with a CHA2DS2-VASc score 2 or greater. 

Major bleeding is explained by the International Society of Thrombosis and Haemostasis (ISTH) as a decline in the hemoglobin of at least two grams per deciliter, or if a patient needs at least two units of packed red blood cells, or if bleeding happens in critical sites, or bleeding that causes death. A non- major bleeding does not satisfy the criteria for major bleeding. Hematuria, epistaxis, gastrointestinal (GI) bleeding, and ecchymosis are the most frequent sites of non-major bleedings. A review of different studies demonstrated that the risk of minor and major bleedings for xabans is not more than warfarin \[[@REF6]\]. Vitamin K antagonists like warfarin have a very narrow therapeutic index, many drug interactions, and also patients need to be monitored regularly \[[@REF31]\]. There have been multiple studies that compared the outcome of patients with AF who are treated with xabans versus warfarin (Table [3](#TAB3){ref-type="table"}).

In a RCT, 27 patients with cirrhosis received direct oral anticoagulants (DOAC) and 18 patients with cirrhosis received warfarin and low molecular weight heparin (LMWH). Only one patient in the DOAC group (4%) had major bleeding compared with five patients in the warfarin and LMWH groups (28%). The rate of thrombosis including ischemic stroke was 4% in the DOAC group vs. 6% in the warfarin and LMWH groups. These results support the preference of DOAC to warfarin and LMWH in patients with liver failure and cirrhosis \[[@REF5]\]. Different clinical trials demonstrated that even in patients with a high-risk profile (elderly, patients with diabetes mellitus, cirrhosis, recurrent stroke, concomitant medications, and severe heart failure) still, xabans are superior to warfarin \[[@REF27]\]. Vitamin K inhibitors inhibit post-translational activation of coagulation factors that are vitamin K dependents. On the other hand, they decrease the production of extrahepatic vitamin k-dependent proteins. This side effect promotes the calcification of heart valves and coronary arteries. Also, it has been shown that the consumption of vitamin K decreases the calcification of coronary arteries and heart valves \[[@REF6]\].

Another randomized controlled study showed that apixaban not only has been superior to warfarin in the prevention of primary endpoints (ischemic stroke and other thromboembolic events), but it also prevents myocardial infarction (12%) \[[@REF1]\]. An RCT compared warfarin with rivaroxaban in patients who use several concomitant medications. The study included the cohort of 5,101 patients with AF who used 0-4 medications, 7,298 patients who took 5-9 concomitant medications, and 1,865 patients who received 10 or more other medications. The concomitant medications were acetylsalicylic acid (ASA), angiotensin-converting enzyme inhibitors, beta-blockers, digitals, and diuretics. The study found out that the risk of stroke or peripheral embolism was not higher in patients who received fewer than 10 concomitant medications, but the risk of major bleeding events and all other causes of death increased by the number of concomitant medications. The risk of major bleeding was 11.64 per 100 patient-years for patients who took 0-4 medications, 14.79 per 100 patient-years for patients who received 5-9 medications, and 23.42 per 100 patient-years for patients who received 10 or more than 10 concomitant medications. In this study, there was not any significant different outcome between rivaroxaban and warfarin across all three groups \[[@REF21]\].

However, two of the selected studies for this review had some different results. In one clinical trial, there was a significantly higher chance of GI bleeding in patients who received rivaroxaban compared to patients who were treated with warfarin (3.61 vs. 2.60 per 100 patient-years) \[[@REF15]\]. Also, in another clinical trial, the efficacy of rivaroxaban vs. warfarin in the prevention of stroke was 1.71 vs. 1.95 per 100 patient-years in older patients (\>75 years) \[[@REF10]\]. The current literature review has some limitations: the study limits its analysis of studies in the previous 10 years on patients who are at least 18 years old, and RCTs and clinical trials who had a full article available. 

Table [3](#TAB3){ref-type="table"} summarizes some of the studies that compared the efficacy and safety of xabans with warfarin in patients with non-valvular AF.

###### Summary of the studies that compared the efficacy and safety of direct factor Xa inhibitors with warfarin.

AF, atrial fibrillation; ECG, electrocardiogram; HF, heart failure; ISTH, International Society of Thrombosis and Haemostasis; xaban, direct factor Xa inhibitor

  ------------------------------------- ----------------------------- ------------------------------------ ---------------------------- --------------------------
  Author/Date                           Study Design                  Subjects Received  Xabans            Subjects Received Warfarin   Total Number of Subjects
  Giugliano et al. \[[@REF4]\], 2013    Randomized controlled trial   7,035 (high dose) 7,034 (low dose)   7,036                        21,105
  Granger et al. \[[@REF1]\], 2011      Randomized controlled trial   9,120                                9,081                        18,201
  Bahit et al, \[[@REF9]\], 2017        Randomized controlled trial   9,088                                9,052                        18,140
  Patel et al. \[[@REF17]\], 2011       Randomized controlled trial   7,131                                7,133                        14,264
  Goodman et al. \[[@REF20]\], 2014     Randomized controlled trial   7,111                                7,125                        14,236
  Bansilal et al. \[[@REF10]\], 2015    Randomized controlled trial   7,131                                7,133                        14,264
  Magnani et al. \[[@REF25]\],  2016    Randomized controlled trial   7,035                                7,036                        14,071
  Fordyce et al. \[[@REF14]\], 2016     Randomized controlled trial   6,359                                6,253                        12,612
  Lopes et al. \[[@REF3]\], 2018        Randomized controlled trial   2,300                                2,300                        4,600
  Hohnloser et al. \[[@REF24]\], 2018   Randomized controlled trial   374                                  187                          561
  Hong et al. \[[@REF13]\], 2017        Randomized controlled trial   95                                   88                           183
  Zhu et al. \[[@REF19]\], 2017         Randomized controlled trial   30                                   30                           60
  ------------------------------------- ----------------------------- ------------------------------------ ---------------------------- --------------------------

Conclusions
===========

This current literature review compared the primary efficacy (the prevention of ischemic stroke) and the incidence of bleeding events in patients who received xabans or warfarin. We aimed to demonstrate that xabans are superior or have at least the same efficacy of warfarin with a slightly less intracranial hemorrhage and major bleeding events. As xabans do not need continuous blood monitoring and less drug interaction, they are superior to warfarin in the prevention of a primary and secondary ischemic stroke in patients with non-valvular AF. Considering patients' age, previous stroke, previous history of any major bleeding, CHA2DS2-VASc scores, and kidney and liver function, xabans have become the first choice of many physicians over warfarin for prevention of primary and secondary stroke in patients with non-valvular AF. Even though the risk of primary outcomes (ischemic stroke) and secondary outcome (any cause of death) increases by age, xabans are still superior to warfarin in the prevention of ischemic stroke events even in patients over 75 years of age. During our review, we found that like major bleedings, non-major bleedings were also more common in patients treated with warfarin.

There are still some challenging questions regarding the potential benefits of xabans over warfarin: Are they going to be approved for valvular AF? What are their other potential benefits over warfarin? Patients with valvular heart disease have more chances for AF, but we found very few studies that evaluated the advantages and disadvantages of xabans vs. warfarin in patients who had significant valvular heart disease and AF. Most studies on xabans excluded patients with moderate to severe mitral stenosis. Due to the limitation of current studies on subjects with valvular AF, the efficacy and safety of xabans vs. warfarin for patients with valvular AF can be tested in future studies.
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